We evaluated the in vitro activity of different antimicrobial combinations with and without colistin against 39 carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains (colistin ! meropenem/ doripenem, colistin ! tigecycline, colistin ! rifampicin, gentamicin ! meropenem, gentamicin ! tigecycline and the double-carbapenem regimen meropenem ! ertapenem) using the chequerboard method. The triple combination colistin ! meropenem ! tigecycline was also tested. In addition, killing studies were performed for meropenem ! ertapenem.
Introduction
Infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp) are associated with high mortality rates. 1 Although various antimicrobial combination regimens have been proposed, the optimal regimen against CR-Kp has not yet been defined. 2 Colistin-based combinations showed in vitro synergistic activity against CR-Kp, even in the presence of colistin-resistant strains. 3 However, colistin use might be limited by the potential nephrotoxicity and the clinical experience in the setting of colistin resistance is still limited. 4, 5 In this challenging scenario, colistin-sparing regimens (i.e. the double-carbapenem regimen) demonstrated both clinical and in vitro efficacy. [6] [7] [8] [9] The aim of this study was to evaluate the in vitro activity of different antimicrobial combinations with and without colistin against CR-Kp, with particular emphasis on the colistin-sparing combination meropenem ! ertapenem (double-carbapenem regimen).
Methods
Over a 3 year period (2013-15), a series of CR-Kp collected from patients with CR-Kp colonization or infection at the Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, Rome, was included in the study.
The MICs of ertapenem, doripenem, meropenem, colistin, gentamicin, rifampicin and tigecycline were determined using the macro broth dilution method. Colistin-based combinations included colistin ! meropenem, colistin ! doripenem, colistin ! rifampicin and colistin ! tigecycline, whereas colistin-sparing combinations were meropenem ! ertapenem, gentamicin ! meropenem and gentamicin ! tigecycline.
The chequerboard (CB) method was used to qualitatively investigate the synergism of all the tested combinations, whereas killing studies were performed only for meropenem ! ertapenem on strains isolated from patients with CR-Kp infection (n " 33).
For CB tests, the fractional inhibitory concentration index (FICI) of each combination was calculated and synergism was defined as FICI 0.5.
In addition, the activity of the triple combination colistin ! meropenem ! tigecycline (expressed as absence of bacterial growth) was assessed. 11 The activity of meropenem, alone and in combination with ertapenem, was investigated by time-kill studies with an initial inoculum of 5%10 5 cfu/mL at the following concentrations: 0.5 % MIC meropenem, 0.5 % MIC ertapenem, 1 % MIC meropenem, 1 % MIC ertapenem, 2 % MIC meropenem, 0.5 % MIC meropenem ! 0.5 % MIC ertapenem, 0.5 % MIC meropenem ! 1 % MIC ertapenem, 1 % MIC meropenem ! 1 % MIC ertapenem, 2 % MIC meropenem ! 1 % MIC ertapenem. Furthermore, for each strain the area under the bactericidal curve (AUBC) for ertapenem and meropenem (alone and in combination) was calculated by plotting the log 10 cfu/mL over time (0-24 h) using the trapezoidal rule. The combination was considered effective if the AUBC was lower than that obtained with the most active single agent at the same concentration. 12 All in vitro experiments were performed in duplicate. Categorical and continuous variables were analysed by using the v 2 test, non-parametric Mann-Whitney tests or linear regression, as appropriate. The number of cfu/mL was expressed as mean + SEM. AUBC values were expressed as mean + SD. Statistical analyses were performed using GraphPad Prism version 7 (GraphPad Software MacKiev).
Results
Overall, 39 strains collected from 39 subjects with CR-Kp infection (n " 33) or colonization (n " 6) were collected. Using the macro broth dilution method, the MIC 50/90 values were 128/512 mg/L for both ertapenem and meropenem, 2/32 mg/L for gentamicin, 64/128 mg/L for doripenem, 0.5/2 mg/L for tigecycline, 2/128 for colistin and 32/512 mg/L for rifampicin, respectively. In particular, 16/39 (41%) strains were resistant to colistin and 10/39 (25.6%) to gentamicin.
Among colistin-free combinations, gentamicin-based combinations were tested against isolates with susceptible and intermediate MICs of gentamicin and showed a high level of synergy (Table 1) .
With respect to colistin-containing regimens, synergy was observed in 18/39 (46.1%), 36/39 (92.3%), 24/39 (61.5%) and 17/39 (43.5%) for colistin ! meropenem, colistin ! rifampicin, colistin ! tigecycline and colistin ! doripenem, respectively.
Interestingly, among colistin-resistant strains (n " 16), synergism was detected in 8/16 (50%), 15/16 (93.7%), 8/16 (50%) and 12/16 (75%) of colistin ! meropenem, colistin ! rifampicin, colistin ! doripenem and colistin ! tigecycline combinations, respectively (Table 1) .
When testing the triple combination, we found an absence of growth at 0.25 % MIC colistin ! 0.25 % MIC meropenem ! 0.5 % MIC tigecycline of 37/39 strains (94.8%) ( Table 1) .
Meropenem ! ertapenem were synergic in 12/39 (30.7%) of the strains using the CB method. In killing studies, both ertapenem and meropenem monotherapy resulted in an initial reduction in log 10 cfu/mL followed by a significant regrowth for all isolates. The combinations 0.5 % MIC meropenem ! 0.5 % MIC ertapenem and 0.5 % MIC meropenem ! 1 % MIC ertapenem were bactericidal at time 24 h only in 5/33 (15.1%) and 13/33 (39.3%) of the strains, respectively, whereas the combinations 1 % MIC meropenem ! 1 % MIC ertapenem and 2 % MIC meropenem ! 1 % MIC ertapenem were bactericidal at time 24 h in 27/33 (81.8%) and 33/33 (100%) of the strains, respectively (Table 2) .
Synergy was observed in 5/33 (15.1%), 20/33 (60.6%), 30/33 (90.9%) and 33/33 (100%) for 0.5 % MIC meropenem ! 0.5 % MIC ertapenem, 0.5 % MIC meropenem ! 1 % MIC ertapenem, 1 % MIC meropenem ! 1 % MIC ertapenem and 2 % MIC meropenem ! 1 % MIC ertapenem, respectively.
Overall, the agreement between the CB method and killing studies was 33%.
The combinations 1 % MIC meropenem ! 1 % MIC ertapenem and 2 % MIC meropenem ! 1 % MIC ertapenem were associated with the lowest mean AUBC values compared with the most active single agent at the same concentration (54.9+26.1 versus 1 % MIC meropenem 134.5+40.1, P , 0.0001 and 44.2+15.3 versus 2 % MIC meropenem 126.4+5.4, P , 0.0001, respectively) ( Table 2) .
When we analysed the results according to carbapenem MICs, we found a significant trend towards an increased antibacterial effect of this combination for isolates with low meropenem MICs up to an MIC value of 128 mg/L; the lower the meropenem MIC, the higher the activity (expressed as AUBC values) of the combination [P " 0.01 (95% CI 0.14-0.8) and P " 0.002 (95% CI 0.26-0.8) for 1 % MIC meropenem ! 1 % MIC ertapenem and 2 % MIC Gentamicin-based combinations were tested against susceptible (n " 24) and intermediate (n " 5) strains. 
Discussion
CR-Kp have spread worldwide and carry an increased risk of mortality compared with susceptible strains. 2 Although considered as the first therapeutic option against CR-Kp, 2,13 polymyxin-and tigecycline-based combinations have raised concerns in terms of toxicity, poor penetration in some tissues and emergence of resistance. 5, 14, 15 Therefore, we aimed at investigating the in vitro activity of colistin-sparing and colistin-based regimens against CR-Kp strains.
Among colistin-free combinations, we showed a high level of synergy for gentamicin-based combinations, whereas meropenem ! ertapenem was synergic in 30.7% of the strains using the CB method. However, we noted that the FICI values in six additional strains were close (i.e. FICI 0.625) to the 0.5 cut-off value for defining synergy; therefore, we could not rule out that a slight synergy could also be observed when testing this combination. To further evaluate these findings, we performed killing curves and we were able to show a potent bactericidal and synergistic activity at 24 h at the concentrations 1 % MIC meropenem ! 1 % MIC ertapenem and 2 % MIC meropenem ! 1 % MIC ertapenem. Since CB and killing studies did not produce comparable results, we could confirm that killing studies should be preferred because they are able to provide quantitative results.
Interestingly, we found that the activity of the doublecarbapenem regimen was related to meropenem MIC value. In fact, the degree of synergy was higher for isolates with lower meropenem MICs, up to an MIC value 128 mg/L, whereas ertapenem MICs did not have an influence on the antibacterial effect.
Based on these results, we could speculate that ertapenem, acting as a suicide inhibitor by saturating the serinecarbapenemase, exerts its action in a concentration-independent manner, thus leading meropenem to bind to the bacterial target, which appears to be dependent on meropenem MIC.
The finding that the activity of the double-carbapenem regimen might be influenced by the exact value of meropenem MICs highlights the importance of performing in vitro synergy analyses whenever a CR-Kp infection is confirmed, in order to guide treatment decisions and predict the potential efficacy of the selected antimicrobial combination. In fact, traditional antimicrobial susceptibility reports appear to be no longer informative for clinicians, especially when carbapenem resistance is expressed as MIC .16 mg/L, as occurs when an automated system is considered. 16 In our experiments, colistin-containing combinations exhibited a high level of synergism, even in the presence of colistin resistance (n " 16), especially with regard to colistin ! rifampicin and colistin ! tigecycline. Furthermore, we were able to show that the triple combination colistin ! meropenem ! tigecycline at subinhibitory concentrations was highly effective, confirming its role in the treatment of CR-Kp infections.
Although the presence of synergy in colistin-containing combinations against colistin-susceptible strains could be explained by the direct antibacterial activity of the drug together with the perturbation of membrane permeability, the high level of synergy in colistin-resistant strains might appear surprising. 17 The ability of colistin to alter (i.e. enhance) membrane permeability might cause hydrophobic and/or large molecules to enter bacteria and exert their antimicrobial action, thus explaining the synergy of unconventional colistin combinations. 18 This detergentlike action of colistin has been hypothesized with regard to colistin ! rifampicin, colistin ! meropenem/doripenem and colistin 100-fold decrease in cfu/mL between the combination and its most active constituent after 24 h. c Difference between the starting inoculum (5.46+0.07 log 10 cfu/mL) and the number of residual viable colonies after 24 h of incubation with the combination. d A negative sign denotes a reduction in inoculum compared with time 0.
e Bacterial regrowth at 24 h was observed for four strains at 1 % MIC meropenem ! 1 % MIC ertapenem, but was not observed at 2 % MIC meropenem ! 1 % MIC ertapenem.
Antimicrobial combinations against carbapenem-resistant K. pneumoniae JAC ! tigecycline combinations by improving the activity of these antibiotics which would otherwise have little effect. 12 A similar mechanism has been proposed for the observed clinical and in vitro effectiveness of colistin plus the double-carbapenem therapy or plus vancomycin. 19, 20 
Conclusions
In conclusion, we showed that colistin-based combinations might be a valid therapeutic option against CR-Kp, even in the presence of colistin resistance. Conversely, colistin-sparing regimens such as meropenem ! ertapenem could represent a viable option when colistin use is not recommended. In addition, we were able to demonstrate a trend towards an increased antibacterial effect of this combination for isolates with lower meropenem MICs, up to an MIC value of 128 mg/L.
Since traditional antimicrobial susceptibility reports are not sufficiently informative for clinicians, we strongly suggest that synergy testing as well as actual meropenem MIC evaluation should always be performed in the case of CR-Kp infections, particularly in the case of bloodstream infections.
